MAN2C1

Across TCGA pan-cancer cohorts, MAN2C1 RNA differs between tumor and matched normal tissue in 10 of 18 cancer types tested, making tumor–normal expression one of MAN2C1’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where MAN2C1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types MAN2C1 is over-expressed in tumor, although a few such as BRCA and LUAD show the opposite, repressed pattern.

LIHC, BRCA, and LUAD are the cancer types where MAN2C1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MAN2C1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	All	III,IV	+0.745	<.001	8	view →
BRCA	Female	All	−0.774	<.001	6	view →
LUAD	Female	All	−0.445	<.001	5	view →
COAD	All	All	+0.404	.001	5	view →
UCEC	All	All	−0.732	<.001	4	view →
CHOL	All	All	+1.340	<.001	3	view →
HNSC	All	III,IV	+0.270	.019	3	view →
STAD	Male	II,III,IV	+0.644	.019	2	view →
KIRC	Female	All	+0.372	.006	2	view →
LUSC	All	All	−0.339	.004	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 10 strongest of 10 lineages.

MAN2C1–LIHC

Open the LIHC breakdown →